Developing antibody-derived therapeutics hinges on ensuring they are manufacturable, safe, and effective. This article delves into the crucial concept of developability assessment in early-stage discovery, focusing on antibodies and their derivatives like bispecific antibodies and antibody-drug conjugates. By screening properties early on, risks of moving suboptimal candidates to later stages are minimized. With computational tools and artificial intelligence aiding in predicting and optimizing antibody properties, the process becomes more efficient and cost-effective.
Antibody-related biological drugs, from monoclonal to bispecific antibodies, are gaining prominence in innovative treatments. The speed at which a candidate progresses from discovery to approval is pivotal in the competitive landscape. Developability, encompassing homogeneity, stability, solubility, and specificity, emerges as a key player in this journey. Physicochemical properties play a significant role in determining a candidate’s developability, affecting its expression, purification, and overall success in the drug development process.
At the discovery stage, thorough screening and optimization are crucial. From initial target identification to antibody generation, a rigorous process involving affinity maturation and humanization takes place. Physicochemical alterations are closely monitored, ensuring the candidate’s suitability for further development. Developability assessment in the discovery stage is distinct from later stages, focusing on rapid evaluations to select optimal candidates for advancement.
Assessing developability-related attributes involves understanding intrinsic properties that impact antibody stability and efficacy. Factors like aggregation, charge distribution, and hydrophobicity influence an antibody’s behavior. Modifications such as disulphide bond formation, cleavage sites, and deamination can significantly affect an antibody’s developability. Strategies like in silico analysis and sequence optimization are employed to mitigate risks and enhance the overall quality of antibody candidates.
By analyzing approved antibody drugs and considering disease indications and administration routes, developability criteria can be tailored to specific projects. Whether dealing with monoclonal antibodies, bispecific antibodies, or antibody-drug conjugates, a holistic approach to assessing developability is essential. From identifying potential risks to implementing optimization strategies, the early-stage discovery sets the foundation for successful antibody-derived therapeutics.
Key Takeaways:
– Early developability assessment is crucial for efficient antibody-derived therapeutic development.
– Physicochemical properties play a significant role in determining antibody developability.
– Intrinsic factors like aggregation tendencies and modifications impact antibody stability and efficacy.
– Tailoring developability criteria based on disease indications and administration routes enhances project success.
Tags: cell culture, yeast, regulatory, chromatography, protein aggregation, protein stability, process development, antibody-drug conjugates, excipients, post-translational modification
Read more on pmc.ncbi.nlm.nih.gov